Core needle biopsy — Tissue sample extraction procedure

A core needle biopsy involves inserting a wide-bore, hollow needle into suspicious tissue under local anaesthesia. Unlike fine-needle aspiration, which collects loose fluid and individual cells, a core needle removes an intact, cohesive sliver of tissue called a core. Clinicians frequently use imaging modalities, including ultrasound, computerised tomography, or magnetic resonance imaging, to guide the needle precisely into the target lesion while avoiding adjacent vital structures.

The resulting tissue specimen preserves the spatial histological architecture of the tumour and its microenvironment. This structural context is critical: it enables pathologists to distinguish between non-invasive conditions, such as ductal carcinoma in situ, and invasive disease. Furthermore, the volume of tissue gathered ensures adequate sample availability for advanced diagnostic methodologies, including immunohistochemistry and comprehensive molecular profiling, establishing the foundation for modern oncology management.

Obtaining a definitive tissue diagnosis via core needle biopsy is often the first decisive step in a cancer pathway. It avoids more invasive surgical biopsies while providing the detailed biological information needed to select therapies accurately. Knowing the precise histological subtype and receptor status prevents unnecessary surgeries, guides the use of pre-operative treatments, and gives patients clarity regarding their exact diagnosis and what future steps to anticipate.

The extracted tissue undergoes formal histological examination, followed by biomarker analysis. Depending on the tissue origin, pathologists test for hormone receptors (ER, PR), HER2 expression, or mismatch repair proteins. The sample is also evaluated for genomic alterations, such as EGFR, BRAF, or KRAS mutations, using next-generation sequencing.

Core needle biopsies are routinely utilised in the evaluation of breast lumps, prostate abnormalities, suspected lymphomas, and soft tissue sarcomas. They are also widely applied to assess lesions in the liver, lungs, kidneys, and peripheral lymph nodes when primary or metastatic tumours are suspected.

The biopsy findings directly dictate the initial treatment strategy. If invasive cancer is verified, molecular tests from the core sample determine eligibility for targeted therapies, immunotherapies, or neoadjuvant chemotherapy before surgery. Conversely, a clear benign result can save a patient from major, unnecessary surgical operations.